Revelation Biosciences, Inc. (REVB) Stock Analysis & Investment Frameworks
Revelation Biosciences, Inc. (REVB) stock analysis on Invetso. Review Revelation Biosciences, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Revelation Biosciences, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Revelation Biosciences, Inc. Key Financial Metrics
- Market Cap: $2.03M
- Revenue: $N/A
- ROE: -100.20%
- ROIC: -104.28%
- Dividend Yield: N/A
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Revelation Biosciences, Inc. Investment Frameworks
Invetso analyzes Revelation Biosciences, Inc. (REVB) across the following frameworks:
- Revelation Biosciences, Inc. 10Y Growth Potential
- Revelation Biosciences, Inc. Scenario Analysis
- Revelation Biosciences, Inc. Risks & Opportunities
- Revelation Biosciences, Inc. Economic Moat
- Revelation Biosciences, Inc. Business Model
- Revelation Biosciences, Inc. Management
- Revelation Biosciences, Inc. SWOT Analysis
- Revelation Biosciences, Inc. Porter's 5 Forces
- Revelation Biosciences, Inc. PESTLE Analysis
- Revelation Biosciences, Inc. ESG Analysis